Neurology, Neuromuscular Disease
-
-
Administers Grant
-
3,4,-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome
-
3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome
-
3,4-Diaminopyridine In Lambert-Eaton Syndrome
-
A MULTICENTER, RANDOMIZED, INVESTIGATOR- AND SUBJECT-BLIND, PLACEBO-CONTROLLED, TREATMENT SEQUENCE STUDY EVALUATING THE SAFETY,
TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH MODERATE TO SEVERE MYASTHENIA GRAVIS
-
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)
-
A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in
-
A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis
-
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
-
A Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Generalized Refractory Myasthenia Gravis (GMG)
-
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients with Generalized Myasthenia Gravis
-
A trial of mycophenolate mofetil in Myasthenia Gravis
-
AANEM Autoimmune Neuromuscular Disorders Fellowship
-
Acetylcholine receptor binding B cells as biomarker for myasthenia gravis
-
Collaborative Agreement between Duke University and True North Therapeutics, Inc.
-
Electrical Impedance Myography and Muscle Ultrasound: Longitudinal Measures in Pompe Disease
-
Exploratory Study of BioMarkers Predicting Response to Immunosuppressives in Myasthenia Gravis
-
High Impact Pilot Project on Myasthenia Gravis and Related Neuromuscular Junction Disorders
-
Immunologic Changes in the Treatment of Myasthenia Gravis
-
Immunologic Studies in Myasthenia Gravis
-
Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
-
Mechanisms of Immune Dysregulation in Chronic Inflammatory Demyelinating Polyneuropathy
-
Metabolic Pathways Of Pathogenic Th17 Cells In Myasthenia Gravis
-
MultiCenter, Randomized, Double-Blind study of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
-
Nerve Ultrasound for Diagnosis and Prognosis of GBS
-
PCORI Study Investigator Meeting
-
PROMISE-MG: PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY OF COMPARATIVE EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MYASTHENIA GRAVIS
-
Pathogenic Th17 cell pathology in CIDP
-
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1)
-
RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS
-
RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS 19-M64
-
Rand,multicenter,DB,placebo-controlled,parallel-group phase III study to investigate the efficacy, safety and tolerability of 2 diff doses of IgPro20(subcutaneious,Ig) for the treatment of chronic inflammatory demyelinating polyneuropathy(CIDP)
-
Role of CD4 T Cell subsets as drivers of MG Diseases -EPM 6568
-
Serimmune/Duke Collaboration (II)
-
Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects with Generalized Myasthenia Gravis
-
Study to Evaluate the Efficacy and Safety of Immune globulin (Human), 10% Caprylate/Chromatography Purified (IGIV -C) as a Corticosteroid Dsparing Agent in Corticosteroid Dependent Patients with Generalized Myathenia Gravis